Home » Topics » Cancer, BioWorld Science

Cancer, BioWorld Science
RSS

AEZS-112 safe, well tolerated in phase I trial in advanced cancer and lymphoma patients

April 30, 2009

Experiments characterize CKD-516, a novel anticancer tubulin-binding agent

April 30, 2009

Neuren and the BCRT establish new company to target breast and other cancers

April 30, 2009

SPA agreement for second phase III trial of OGX-011 in prostate cancer

April 29, 2009

Bayer and Ardea enter global MEK inhibitors agreement for cancer indications

April 29, 2009

Takeda discloses Polo-like kinase inhibitors for the treatment of cancer

April 29, 2009

Celsion enrolls first patient in ThermoDox phase I/II breast cancer trial

April 29, 2009

PF-04929113 well tolerated in ongoing first-in-man study in cancer patients

April 29, 2009

Dual antibody Sym-004 shows anticancer promise in vitro and in vivo

April 29, 2009

Cylene Pharmaceuticals presents data on CK2 inhibitor CX-4945

April 29, 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 15, 2026.
AAIC 2026: Age of amyloid is being joined by time of tau
BioWorld
The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...
Celia trial: data strong, analysts skeptical
BioWorld
Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026
Rethinking anorexia: A disorder of mind and metabolism
BioWorld Science
Anorexia nervosa (AN) is a complex and severe eating disorder that has long been considered a psychiatric condition driven by distorted body image and maladaptive...